ESMO 2017 | PARP inhibitors: game-changers for ovarian cancer patients?
Mansoor Mirza, MD, from the Copenhagen University Hospital, Copenhagen, Denmark talks to us to explain recent efforts that have been made to find an effective new treatment for patients of ovarian cancer. He discusses two Phase III clinical trials exploring the potential of PARP inhibitors in the therapy of ovarian cancer. The NOVA trial (NCT01847274) assessed the efficacy of niraparib while the ARIEL3 study (NCT01968213) aimed to determine the efficiency of rucaparib. Dr Mirza talks about the results and tells us about the need to develop tests which can identify patients who will respond well to these treatments. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference in Madrid, Spain.
Get great new content delivered to your inboxSign up